Oxford Biomedica (NASDAQ:OXBDF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, October 18th. The brokerage currently has a $0.25 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 127.27% from the stock’s current price.
According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “
Oxford Biomedica (NASDAQ:OXBDF) opened at 0.11 on Wednesday. Oxford Biomedica has a 52-week low of $0.09 and a 52-week high of $0.14. The firm’s market cap is $339.71 million. The firm’s 50-day moving average is $0.12 and its 200-day moving average is $0.12.
TRADEMARK VIOLATION WARNING: “Oxford Biomedica (OXBDF) Stock Rating Upgraded by Zacks Investment Research” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/27/oxford-biomedica-oxbdf-upgraded-by-zacks-investment-research-to-buy.html.
About Oxford Biomedica
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
Get a free copy of the Zacks research report on Oxford Biomedica (OXBDF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.